From A to Z: Navigating Outpatient IMDYLLTRA® Therapy for Clinical Practice

Date: **1 October 2026** | Time: **18:00 – 19:00** | Where: **Online**

Dr. med. Laetitia Mauti
Kantonsspital Winterthur

Prof. Dr. med. et Dr. phil. nat. Sacha Rothschild
Kantonsspital Baden

Why attend?

- Gain practical insights into managing IMDYLLTRA® therapy in the outpatient setting
- Learn how to navigate the patient journey from treatment initiation to ongoing monitoring
- Discuss practical challenges and solutions for integrating therapy into clinical practice
- Engage directly with experts during the live Q&A

Registration

To register, scan the QR code or contact us via email at: info@medtis.ch

medtis.ch

Financially supported by Amgen Switzerland AG

AMGEN

Organisation

medtis

09/2026
CHE-757-26-80044

Abbreviated information for healthcare professionals
IMDYLLTRA® (tarlatamab): A bispecific DLL3-directed CD3 T-cell engager produced using recombinant DNA technology. **Indication:** IMDYLLTRA is used to treat adult patients with locally advanced or metastatic small cell lung cancer (SCLC) whose disease has progressed during or after platinum-based chemotherapy. **Dosage/Administration:** IMDYLLTRA should only be administered under the guidance of healthcare professionals experienced in the treatment of malignancies, cytokine release syndrome (CRS) and neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS). It should be administered in a suitable healthcare facility. The recommended dosage and dosage regimen consist of IV infusions within one-hour period at an initial dose of 1 mg on Cycle 1 Day 1, followed by 10 mg on Days 8 and 15 and then every two weeks. Patients should receive treatment until disease progression or unacceptable toxicity. Patients should be monitored on Day 1 and Day 8 of Cycle 1 for six to eight hours from the start of the infusion. For subsequent infusions, patients should be monitored at the doctor‘s discretion. On Day 1 and Day 8, patients should be advised to remain in proximity of a suitable healthcare facility, accompanied by a caregiver, for 48 hours from the start of each IMDYLLTRA infusion. Both patients and caregivers should be instructed on the signs and symptoms of CRS and ICANS before discharge. Concomitant medication: On Day 1 and Day 8 of Cycle 1, 8 mg IV dexamethasone (or equivalent) should be administered within 1 hour prior to administration of IMDYLLTRA; intravenous administration of 1 L normal saline over a period of two to four hours is recommended immediately after completion of the IMDYLLTRA infusion, in line with the standard of care. **Contraindications:** Hypersensitivity to the active substance or any of the excipients. **Warnings and precautions:** Administration of IMDYLLTRA can be associated with CRS, which may be serious, life-threatening or fatal. Administration of IMDYLLTRA can be associated with ICANS, which may be serious or life-threatening. Patients should be closely monitored for relevant signs and symptoms. IMDYLLTRA has been associated with cytopenias, including neutropenia, thrombocytopenia and anaemia, as well as with serious infections, hepatotoxicity and hypersensitivity reactions. Both before and during treatment, patients should be monitored as outlined in the Information for healthcare professionals, which includes monitoring of complete blood count, liver enzymes and bilirubin levels, and for any signs of infection and hypersensitivity. **Interactions:** No formal interaction studies have been conducted. Starting IMDYLLTRA treatment causes a transient release of cytokines, which may suppress CYP450 enzymes and increase exposure to concomitantly administered CYP substrates. Patients receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, must be closely monitored. **Pregnancy/lactation:** Women of childbearing potential should use a reliable method of contraception during treatment with IMDYLLTRA and for two months after the last dose. IMDYLLTRA should not be administered during pregnancy unless clearly necessary. Breast-feeding is not recommended during treatment with IMDYLLTRA and for two months after the last dose. **Undesirable effects:** Very common: CRS, decreased appetite, pyrexia, dysgeusia, constipation, anaemia, fatigue, nausea, asthenia, neutropenia, hyponatraemia, headache, lymphopenia, vomiting, weight decreased, hypokalaemia, alanine aminotransferase increased, dyspnoea and pruritus. Common: ICANS, tremor, confusional state, delirium, thrombocytopenia, leukopenia, increased aspartate aminotransferase, decreased white blood cell count, rash, chills, hypomagnesaemia, myalgia, dizziness. Uncommon: Neurotoxicity, seizure, ataxia, encephalopathy. **Packs:** Packs containing one vial of 1 mg or 10 mg IMDYLLTRA and two vials of 7 mL solution stabiliser. **Sales category:** A. **Marketing authorisation holder:** Amgen Switzerland AG, Risch; domicile: 6343 Rotkreuz. IMDYLLTRA_v2.0

▼ This medicinal product is subject to additional monitoring. For more information, please see the Information for healthcare professionals for IMDYLLTRA at www.swissmedicinfo-pro.ch.